NEW YORK, Feb. 13, 2017 /PRNewswire/ -- Recombinant Drugs to 2020 Products, Players, Markets and Forecasts
Evolving Markets for Tailored Therapeutics
In recent years, the number of recombinant drugs including engineered biological drugs in development has increased significantly. The pace of this growth is encouraging suppliers to view competitors in new ways. Cooperation between and among
drug developers and drug producers is occurring much earlier in the drug development cycle, allowing participants to improve supply chains and time-to-market. The result is a rapidly growing market sector that is changing disease therapeutics on a global scale. This report examines FDA and EMA-approved biological drugs and their position and potential in a dozen major disease segments markets with important implications for drug developers, contract and supply chain partners and infrastructure participants. Growth prospects for key biological drug therapeutic segments will vary over the forecast period covered in this analysis, influenced by demographic, socioeconomic and competitive factors.Evolution in Drug StrategiesA longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic availability and cost-of-delivery, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application."This report examines FDA and EMAapproved biological drugs and their position and potential in a dozen major disease segments markets with important implications for drug developers, contract and supply chain partners and infrastructure participants. Growth prospects for key biological drug therapeutic segments will vary over the forecast period covered in this analysis, influenced by demographic, socioeconomic and competitive factors."What You Will Learn- What are the currently approved biological drugs; their host system, indication(s)?- What are the key market segments for biological drugs; what is the competitive picture for each segment?- What are the drug classes, therapeutic classes and market segments that comprise the global market for biological drugs?- What are the supply chain dynamics of biological drug sourcing and commercialization?- What is the revenue picture for each drug/class? What will it look like in 2020?- Who are the leading biological drug suppliers, and what are the key collaborations in the sourcing cycle?- What is the drug landscape for key market segments? What is the market share? What is the size?Development- Drug Developers- Device Suppliers- CMOs- Components/APIs- Testing/Validation- Clinical Trial MgmtIndustry- Pharma Managers- Biotech Managers- Drug Marketers- Industry Strategists- Financial Analysts- Management ConsultantsMarket- Clinical Managers- Drug Distributors- Pharma Regulators- FDA Consultants- Managed Care ManagersRead the full report: http://www.reportlinker.com/p04694753-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com__________________________Contact Clare: firstname.lastname@example.orgUS: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/recombinant-drugs-to-2020-300406642.html